Shares of Palantir Technologies fell 3.7% to $131.47 Tuesday after Britain's government confirmed a formal review of the company's £330 million ($441 million) contract to build a data platform linking National Health Service records. Technology minister Liz Kendall said the review would assess whether to extend the deal — which can run up to seven years — or terminate it using a break clause in early 2027. The news lands on a stock already down roughly 14% year-to-date, sliding from $152 a week ago amid broader tech weakness.
A Parliamentary Committee Called Palantir an "Unacceptable" Risk. The UK Science, Innovation and Technology Committee singled out Palantir as the most concerning tech provider to the public sector, warning that Britain risked becoming overly dependent on a single foreign firm for critical health infrastructure.
Separately, London's mayor last month blocked a £50 million police contract with the company, citing ethics concerns. The political mood in Westminster is clearly shifting against the company.
The UK Is Palantir's Second-Largest Market — And It's Shrinking in Importance. The UK accounted for about 11% of Palantir's global revenue in 2024, roughly $305 million. The NHS deal alone is worth $441 million over its full term. But Q1 2026 revenue surged 85% year-over-year to $1.63 billion , and management raised full-year guidance to roughly $7.65–$7.66 billion. Losing the NHS contract would dent international revenue, but it represents roughly 6% of projected annual sales — painful, not fatal.
The Real Threat Is Contagion, Not Just One Contract. Palantir has secured more than £500 million in UK public sector work, including contracts with the Ministry of Defence, police forces, and financial regulators. If the NHS review emboldens other European governments to question reliance on U.S. tech suppliers — a growing trend called "digital sovereignty" — the pipeline risk extends well beyond Britain. The episode sits inside a wider European argument about reliance on US providers for critical infrastructure.
Sky-High Valuation Leaves No Room for Stumbles. Palantir trades at nearly 62 times forward sales, a valuation difficult to justify unless the company remains one of the biggest winners in the enterprise AI market.
The numbers are extraordinary, but the premium assumes they continue indefinitely — any slip produces sharp downside. At these levels, even a mid-sized contract loss becomes a sentiment event. Investors should watch the review's conclusion, expected before year-end, as a bellwether for Palantir's broader sovereign-government strategy.